Review Objectives
The general objective of this systematic review is to critically appraise, synthesise and present the evidence on determinants of non-compliance to Anti Retro viral Treatment among adults living with HIV/AIDS.
More specifically, the focused objectives of this systematic review are to provide summarised evidence on: ART is a 'holistic' treatment, which not only involves taking ARV drugs, but understanding HIV/AIDS and ART, preparing for and complying to a course of ARV therapy, ensuring proper nutrition, psychosocial support, palliative care and caring for the caregivers of peoples living with HIV/AIDS. There has been a significant decline in mortality and morbidity associated with HIV/AIDS following the introduction of HAART across Europe; In 1998, death rates fell to one-fifth of the total deaths before the introduction of HAART 4 and mortality and morbidity have declined by suppression of viral replication, restoration and preservation of immune function, and prevention of drug resistance.
There are a number of problems associated with HAART, including the development of drug resistance, the difficulties of maintaining compliance long-term adherence and drug-related toxicities 5 all of which may lead to virological failure, which in turn leads to immunological failure and clinical progression of HIV/AIDS. 6, 7, 8 Compliance to HAART is therefore critical to the survival of HIV/ AIDS infected people. 9 The clinical efficacy of antiretroviral therapies (ART) in suppressing the HIV and improving survival rates for those living with HIV has been well documented. [10] [11] [12] [13] [14] However, successful antiretroviral treatment is dependent on sustaining high rates of compliance (correct dosage, taken on time and in the correct wayeither with or without food). The optimal compliance/minimum level of compliance required for antiretrovirals (ARVs) medication to work effectively is 95%. 15 . So, near perfect pill taking (values exceeding 95%) is desirable in order to maximise the benefits of ART. This means taking the correct dose of drugs at the right times and observing any dietary restrictions. Anything less than this level of compliance leads rapidly to the development of viral resistance and hence to much earlier treatment failure. 16 Although combinations of several ARV regimens can allow for effective viral suppression at moderate levels of compliance [16] [17] [18] , none or sub-optimal compliance can lead to the development of drug-resistant strains of the HIV. 20 A person who takes ARVs erratically may only receive marginal benefit from treatment, but will suffer from side effects of the drugs 19 that results in the opportunity of the virus(s) to adapt to the ARV medications. It is important that all patients can demonstrate an understanding of this before starting treatment. A patient who stops taking ARV entirely will rapidly lose any benefit they may have received in terms of increased immunity as the virus flourishes and CD4+ cells are destroyed. 19 Non-compliance to ART is therefore a major public health concern as it leads to virological, immunological and clinical failure as it increases the risk of transmission of drug resistant virus. 20 The major risk factors of non-compliance to ART are thought to be forgetfulness, lack of understanding of treatment benefits, severity of adverse events, and the level of complexity of the drug regimen. 9 A randomised clinical trial (RCT) study conducted in USA from June 2008 through July 2009 on characterised rates and correlates of ART adherence among 242 older (50 years and older) HIV-infected persons indicated, rates of compliance and determinants of depression did not differ by gender but avoidance coping, social support and depression determined ART compliance in older men, but not in older women. 21 Many factors have been cited as reasons for non-compliance in studies of Western countries. 22 A study conducted in U.S.A (North Carolina), indicated actual adherence rates are often far lower and patients offer a range of reasons for non compliance to ART like forgetting, being away from home, being busy, or experiencing a change in daily routine, psychiatric disorders, such as depression or substance use/abuse, uncertainty about the effectiveness of treatment and the consequences of poor adherence, regimen complexity, and treatment side effects. 22, 23 A study conducted in Italy (Rome) indicated symptoms and adverse drug effects, psychological distress, lack of social or family support, complexity of the HAART regimen, low patient self-efficacy, and inconvenience of treatment were the factors most consistently associated with non-compliance. 24 In the south of Africa, common determinants thought to be non-compliance to ART were fear of A study conducted in South Africa (KwaZulu-Natal), also indicated that poor environmental factors were associated with poor compliance. 30 Reasons reported for non-compliance to ART in resource limited countries include forgetting, travel, fear of disclosure, shortage of pills, difficult schedules, medication cost, lack of access and privacy. 31 A study conducted in Yirgalem Hospital (South Ethiopia), in 2006, suggested that in this population -medication adverse effects, distance to health facility and caring for children, were independent determinants of noncompliance to ART among people living with HIV/AIDS. 32 In these countries where older first-line therapies like zidovudine, lamivudine and abacavire 2 are being used, the development and transmission of drug-resistant strains of HIV often greatly limit the treatment options available. In these countries, financial constraints, disruption in access to medications, issues related to gender, 33 48, 49 To date, to our knowledge, there are no systematic reviews that have examined the determinants of noncompliance to ART among adult living with HIV/AIDS with similar objectives this review. Therefore, this review will aim to provide the best available evidence for the determinants of non-compliance to ART among adult peoples living with HIV/AIDS.
For this systematic review, the following definitions will be used 
Inclusion Criteria

Types of participants
This review will consider adults (18 years and older) living with HIV/AIDS who have initiated ARV treatments, who live in either developed or developing countries as defined by the World Bank.
Focus of interest
The focuses of interest for this review are determinants of non-compliance to Antiretroviral Therapy among adults living with HIV/AIDS.
Types of outcome measures
This review will include studies that have identified determinants of non-compliance to Antiretroviral 
Types of studies
This review will consider any quantitative evidence from Observational analytical Epidemiological study designs like prospective and retrospective cohort studies, case control studies that have identified determinants of non-compliance to Antiretroviral Therapy among adults living with HIV/AIDS for the review. Descriptive cross-sectional and case-series/report studies will not be considered for inclusion in the review.
Search strategy
The search strategy aims to find published studies in English language only between January 1997 and December 2011. The search will focus on key elements of the review objectives (participants, focuses of interest, comparators and outcome) and a thorough search strategy will be undertaken as per the following three steps:
1. An initial limited search will be searching of studies on MEDLINE, CINAHL followed by analysis of the text words contained in the title and abstract and of the index terms used to describe article.
2. A second search will be by using all identified keywords and index terms across all included databases.
3. The Third step will be searching the reference list of all identified reports and articles for the final analysis.
4.
The databases to be searched include: Electronic search will be conducted through PubMed, CINAHL, EMBASE, Mednar and ProQuest. Government websites, and specific journals accessed through HINARI, Popline, will be searched.
Initial keywords to be used will be: The following search strategy will be modified for the various databases and search engines. 
Assessment of methodological quality
All papers selected for inclusion in the review will be subjected to a rigorous, independent appraisal by two critical appraisers. Any studies selected for retrieval will be assessed by two independent reviewers for their methodological validity prior to inclusion in the review by using the standardised JBI critical appraisal instruments from the Joanna Briggs Institute called Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data Collection
Data will be extracted from papers included in the review by using the standardised data extraction tool from JBI-MAStARI (Appendix II).
Data Synthesis
Quantitative papers will be pooled in statistical meta-analysis using the JBI-MAStARI. Effect sizes expressed as odds ratio or risk ratio or relative risk and their 95% confidence intervals will be calculated for analysis. Heterogeneity of the study will be assessed statistically using the standard Chi-square test and explored also using subgroup analyses based on the different study designs included in this review.
Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
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